Treatment with Ocrevus (ocrelizumab) decreased levels of neurofilament light chain (NfL) and immune B-cells in the blood serum and central nervous system of patients with relapsing MS, according to...
Rates of sexual dysfunction and related distress are higher among women with MS than those without the condition. That is according to research published in the Journal of Sexual Medicine.
In the...
A new 48-week study of the investigational drug evobrutinib in patients with relapsing remitting MS (RRMS) showed it reduced the number of enhanced MRI lesions (T1 gadolinium-enhancing lesions) among...
The National Institute for Health and Care Excellence (NICE) has approved ocrelizumab (Ocrevus) for treating patients in England with early primary progressive multiple sclerosis (PPMS). Patients...
The European Medicines Agency (EMA) has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of a range of potentially serious side effects. These side...
Healthcare Improvement Scotland has published revised standards to help health and social care professionals improve the care and support provided for the estimated one million adults in Scotland...
Inflammation and demyelination are the main processes in multiple sclerosis (MS). However, to date, blood biomarkers of inflammation are lacking. TWEAK, a transmembrane protein that belongs to the...
Some studies have suggested that minerals such as zinc and iron may play a role in how multiple sclerosis (MS) progresses after diagnosis, but little was known about whether zinc, iron and other...
The US Food and Drug Administration has approved siponimod (Mayzent) tablets to treat adults with relapsing forms of multiple sclerosis (MS), which will include clinically isolated syndrome,...
Brain stem cells in people with the more advanced forms of multiple sclerosis (MS) look much older than they really are, according to a study led by UConn Health and published in the Proceedings of...
